Fulminant Demyelinating Diseases

The Neurohospitalist

Volumn 3, Issue 2, 2013, Pages 81-91

  Rahmlow, Megan R ^a   Kantarci, Orhun ^a  

^a MAYO CLINIC   (United States)

Author keywords

ADEM; fulminant MS; Marburg; neuromyelitis optica; tumefactive MS

Indexed keywords

EID: 84992828894     PISSN: 19418744     EISSN: 19418752     Source Type: Journal    
DOI: 10.1177/1941874412466873     Document Type: Article

References (69)

1. Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol. 2005; 62(11):1673–1680.
2. Marchioni E, Ravaglia S, Piccolo G, et al. Postinfectious inflammatory disorders: subgroups based on prospective follow-up. Neurology. 2005; 65(7):1057–1065.
3. Hynson JL, Kornberg AJ, Coleman LT, et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 2001; 56(10):1308–1312.
4. Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000; 123(Pt 12):2407–2422.
5. Leake JA, Albani S, Kao AS, et al, Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical, and laboratory features. Pediatr Infect Dis J. 2004; 23(8):756–764.
6. Alper G, Heyman R, Wang L. Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features. Dev Med Child Neurol. 2009; 51(6):480–486.
7. Wender M. Acute disseminated encephalomyelitis (ADEM). J Neuroimmunol. 2011; 231(1-2):92–99.
8. Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002; 59(8):1224–1231.
9. De Seze J, Debouverie M, Zephir H, et al. Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol. 2007; 64(10):1426–1432.
10. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology. 2001; 56(10):1313–1318.
11. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007; 68(16 suppl 2):S7–S12.
12. Young NP, Weinshenker BG, Parisi JE, et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain. 2010; 133(Pt 2):333–348.
13. Honkaniemi J, Dastibar P, Kahara V, Haapasalo H. Delayed MR imaging changes in acute disseminated encephalomyelitis. Am J Neuroradiol. 2001; 22(6):1117–1124.
14. Rossi A. Imaging of acute disseminated encephalomyelitis. Neuroimag Clin N Am. 2008; 18(1):149–161.
15. Soneville R, Demeret S, Klein I, et al. Acute disseminated encephalomyelitis in the intensive care unit: clinical features and outcome of 20 adults. Intensive Care Med. 2008; 34(3):528–532.
16. Balasubramanya KS, Kovoor JM, Jayakumar PN, et al. Diffusion-weighted imaging and proton MR spectroscopy in the characterization of acute disseminated encephalomyelitis. Neuroradiology. 2007; 49(2):177–183.
17. Callen DJ, Shroff MM, Branson HM, et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology. 2009; 72(11):968–973.
18. Verhey LH, Branson HM, Shroff MM, et al. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol. 2011; 10(12):1065–1073.
19. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292–302.
20. Ketelslegers IA, Visser IER, Neuteboom RF, Boon M, Catsman-Berrevoets CE, Hintzen RQ. Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children. Mult Scler. 2010; 17(4):441–448.
21. Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol. 2009; 31(4):439–453.
22. Von Stuckrad-Barre S, Klippel E, Foerch C, Lang JM, du Mesnil de Rochemont R, Sitzer M. Hemicraniectomy as a successful treatment of mass effect in aute disseminated encephalomyelitis. Neurology. 2003; 61(3):420–421.
23. Refai D, Lee MC, Goldenberg FD, Frank JI. Decompressive hemicraniectomy for acute disseminated encephalomyelitis. case report. Neurosurgery. 2005; 56(4):E872.
24. Takata T, Hirakawa M, Sakurai M, Kanazawa I. Fulminant form of acute disseminated encephalomyelitis: successful treatment with hypothermia. J Neurol Sci. 1999; 165(1):94–97.
25. Ryan LJ, Bowman R, Zantek ND, et al. Use of therapeutic plasma exchange in the management of acute hemorrhagic leukoencephalitis: a case report and review of the literature. Hemapheresis. 2007; 47(6):981–986.
26. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology. 2003; 61(10):1373–1377.
27. Wattamwar PR, Baheti NN, Kesavadas C, Nair M, Radhakrishnan A. Evolution and long-term outcome in patients presenting with large demyelinating lesions as their first clinical event. J Neurol Sci. 2010; 297(1-2):29–35.
28. Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008; 131(Pt 7):1759–1775.
29. Masdeu JC, Moreira J, Trasi S, et al. The open ring. A new imaging sign in demyelinating disease. J Neuroimaging. 1996; 6(2)104–107.
30. Comi G. Multiple sclerosis: pseudotumoral forms. Neurol Sci. 2004; 25(suppl 4):S374–S379.
31. Krivickas LS, Hochberg FH, Freeman S. Chronic inflammatory demyelinating polyradiculoneuropathy with tumefactive central demyelination. Muscle Nerve. 2006; 33(2):283–288.
32. Kiriyama T, Kataoka H, Taoka T, et al. Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30mm. J Neuroimaging. 2011; 21(2):e69–e77.
33. Masdeu JC, Quinto C, Olivera C, Tenner M, Leslie D, Visintainer P. Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology. 2000; 54(17):1427–1433.
34. Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology. 2004; 62(2):226–233.
35. Seewann A, Enzinger C, Filippi M, et al. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: a review of reported findings. J Neurol. 2008; 255(1):1–10
36. Miller RC, Lachance DH, Lucchinetti CF, et al. Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys. 2006; 66(4):1178–1186.
37. Poser CM, Goutieres F, Carpentier MA, Aicardi J. Schilder’s myelinoclastic diffuse sclerosis. Pediatrics. 1986; 77(1):107–112.
38. Mehler MF, Rabinowich L. Inflammatory myelinoclastic diffuse sclerosis (Schilder's disease): neuroradiologic findings. AJNR. 1989; 10(1):176–180.
39. Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol. 1993; 33(1):18–27.
40. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6(9):805–815.
41. Kim W, Kim SH, Lee SH, et al. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler. 2011; 17(9):1107–1112.
42. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364(9451):2106–2112.
43. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010; 17(8):1019–1032.
44. Cabrera-Gomez J, Kister I. Conventional brain MRI in neuromyelitis optica. Eur J Neurol. 2011; 19(6):812–819
45. Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011; 76(14):1229–1237.
46. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol. 2008; 10(1):55–66.
47. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006; 63(3):390–396.
48. Magna SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009; 72(8):712–717.
49. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002; 127(Pt 7):1450–1461.
50. Roemer SF, Parisi JE, Lennon VA, et al. Pattern specific loss of aquaporin 4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007; 130(Pt 5):1194–1205.
51. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003; 60(5):848–853.
52. Matsushita T, Isobe N, Piao H, et al. Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status. J Neurol Sci. 2010; 291(1-2):37–43.
53. Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999; 46(6):878–886.
54. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2011; 76(3):294–300.
55. Magana SM, Keegan M, Weinshenker BG, et al, Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011; 68(7):870–878.
56. Keegan M, Konig F, McClelland R, et al. Relationship between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005; 366(9485):579–582.
57. Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology. 2000; 54(6):1370–1372.
58. Marchioni E, Marinou-Aktipi K, Uggetti C, et al. Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis. J Neurol. 2002; 249(1):100–104.
59. Pradhan S, Gupta RP, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci. 1999; 165(1):56–61.
60. Turatti M, Gajofatto A, Rossi F, Vedovello M, Benedetti MD. Long survival and clinical stability in Marburg’s variant multiple sclerosis. Neurol Sci. 2010; 31(6):807–811.
61. Nozaki K, Abou-Fayassal N. High dose cyclophosphamide treatment in Marburg variant multiple sclerosis: A case report. J Neurol Sci. 2010; 296(1-2):121–123.
62. Jeffery DR, Lefkowitz DS, Crittenden JP. Treatment of Marburg variant multiple sclerosis with mitoxantrone. J Neuroimaging. 2004; 14(1):58–62.
63. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optic spectrum disorder? Mult Scler. 2012; 18(10):1480–1483.
64. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficancy, and predictors of benefit in neuromyelitis optica. Neurology. 2011; 77(7):659–666.
65. Jacob A, Matiello M, Weinshenker B, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009; 66(9):1128–1133.
66. Jacob A, Weinshenker B, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008; 65(11):1443–1448.
67. Ragel BT, Fassett DR, Baringer JR, Browd SR, Dailey AT. Decompressive hemicraniectomy for tumefactive demyelination with transtentorial herniation: observation. Surg Neurol. 2006; 65(6):582–583.
68. Censori B, Agostinis C, Partziguian T, Gazzaniga G, Biroli F, Mamoli A. Large demyelinating brain lesion mimicking a herniating tumour. Neurol Sci. 2001; 22(4):325–329.
69. Gonzalez Sanchez JJ, Ensenyat NJ, de Notaris M, Arboix JR, García CG, Rodríguez EF. A case of malignant monophasic multiple sclerosis (Marburg’s disease type) successfully treated with decompressive hemicraniectomy. J Neurol Neurosurg Psychiatry. 2010; 81(9):1056–1057.